News of the WeekCancer Research

Transatlantic War Over BRCA1 Patent

See allHide authors and affiliations

Science  08 Jun 2001:
Vol. 292, Issue 5523, pp. 1818
DOI: 10.1126/science.292.5523.1818

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


PARIS-- Last week, the Institut Curie announced the discovery of a newly identified mutation in BRCA1, a human gene linked to elevated risk for breast and ovarian cancer, with a broadside against Myriad Genetics, which has developed an automated test for mutations in this gene and the related BRCA2. Because Myriad's test doesn't pick up defects like the newly identified mutation, Curie claimed, it represents "a potential danger" to French cancer patients. The attack is the opening volley in a battle over Myriad's right to market its test in Europe.